Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 17/20 | 0.61 |
| ▸ | STS | P08842 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18872545 | 0.88 | STS (0.66) | ALDH2STSKDM4EMEN1NPC1 | |
| SCHEMBL14755355 | 0.85 | ALDH2 (0.58) | ALDH2KDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL16372524 | 0.84 | STS (0.76) | ALDH2STSKDM4EMEN1NPC1 | |
| SCHEMBL14740649 | 0.84 | STS (0.64) | ALDH2STSKDM4EMEN1NPC1 | |
| SCHEMBL14740635 | 0.80 | STS (0.56) | ALDH2STSKDM4EMEN1NPC1 | |
| SCHEMBL2107264 | 0.79 | MAOB (0.52) | ALDH2ALDH1A1MAPT | |
| SCHEMBL14755324 | 0.78 | ALDH2 (0.71) | ALDH2 | |
| SCHEMBL17718166 | 0.78 | STS (0.57) | ALDH2STSKDM4EMEN1NPC1 | |
| SCHEMBL17718161 | 0.78 | STS (0.57) | ALDH2STSKDM4EMEN1NPC1 | |
| SCHEMBL2107958 | 0.78 | MAOB (0.52) | ALDH2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751090-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | Gilead Sciences, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-8673966-B2 | ALDH-2 inhibitors in the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130231325-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | GILEAD SCIENCES. INC. (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2013033377-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231325-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH1B1 | ALDH2 5/4885STS 832/4885KDM4E 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.